Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. 29. Juli 2019 A Welt, M K Welslau, D Lüftner, M Deryal, R Liersch, J Sahlmann, L Houet, C Vannier, N Marschner, K Potthoff, 2019. Ann Oncol Volume 30, Issue Supplement_3, May 2019, mdz100.007, https://doi.org/10.1093/annonc/mdz100.007 Abstract Patient-based prospective real-world data analysis shows that the duration of treatment interruptions with subsequent resumption of idelalisib therapy can vary from days to months. Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., von Troostenburg, A., Ramroth, H., Abenhardt, W., Rummel, M., 2019. HemaSphere 3 (PS1163), 528–529. https://doi.org/10.1097/01.HS9.0000562936.05518.43… Weiterlesen Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL. M Boegemann, J Bedke, M Schostak, C Hering-Schubert, M Welslau, J Schleicher, T Wolf, A Petzoldt, C Doehn, C Grüllich, V Grünwald, T Steiner, A… Weiterlesen